share_log

Berenberg Initiates Coverage On Blueprint Medicines With Buy Rating, Announces Price Target of $90

Berenberg Initiates Coverage On Blueprint Medicines With Buy Rating, Announces Price Target of $90

貝倫伯格以買入評級啓動藍圖藥品保險,宣佈目標價爲90美元
Benzinga Real-time News ·  2022/09/14 06:46

Berenberg analyst Zhiqiang Shu initiates coverage on Blueprint Medicines (NASDAQ:BPMC) with a Buy rating and announces Price Target of $90.

貝倫伯格分析師舒志強以買入評級開始對藍圖藥品(納斯達克股票代碼:BPMC)進行報道,並宣佈目標股價爲90美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論